← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-11 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3,526개
CGTBiologicstaleMarino Biotechnology Co., Ltd.Phase 1

autologous anti-CD19 CAR T cells (autologous anti-CD19 CAR T cells)

B-cell Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes (autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes)

Melanoma; Skin Cancer · Melanoma

#Melanoma#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes (autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes)

Skin Cancer; Melanoma · Skin Cancer

#SkinCancer#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 DISCONTINUED
CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

autologous anti-gp 100:154-162 T-cell receptor gene-engineered tumor infiltrating lymphocytes (autologous anti-gp 100:154-162 T-cell receptor gene-engineered tumor infiltrating lymphocytes)

Skin Cancer; Melanoma · Skin Cancer

#SkinCancer#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 DISCONTINUED
CGTBiologicstaleThe Affiliated Nanjing Drum Tow…Phase 1

autologous decidual-like NK cells (autologous decidual-like NK cells)

Abortion, Habitual; Infertility Unexplained · Abortion, Habitual

#AbortionHabitual#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstaleJoshua Sasine, MD, PhDPhase 1

autologous hematopoietic stem cells added to planned CAR T (autologous hematopoietic stem cells added to planned CAR T)

Hematologic Malignancy; Large B-cell Lymphoma · Hematologic Malignancy

#HematologicMalignancy#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
AntibodystaleAbbViePhase 3

adalimumab (Humira, azathioprine or adalimumab and infliximab)

Crohn Disease · Crohn Disease

#CrohnDisease#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleMedical University of GrazApproved

etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept (bDMARD withdrawal, bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept))

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Approved#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleSeoul National University Hospi…Phase 2

bendamustine plus rituximab (bendamustine plus rituximab)

Marginal Zone B-cell Lymphoma · Marginal Zone B-cell Lymphoma

#MarginalZoneB-cellLymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 81.8%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

bevacizumab, Rituximab (bevacizumab, Rituximab)

Non-Hodgkin's Lymphoma; B-cell Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 93.8%임상시험 1상태 DISCONTINUED
AntibodystaleUniversity Hospital, CaenPhase 2

bevacuzimab spray (bevacuzimab spray)

Telangiectasia, Hereditary Hemorrhagic · Telangiectasia, Hereditary Hemorrhagic

#TelangiectasiaHereditaryHemorrha#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
CGTBiologicstaleShenzhen Geno-Immune Medical In…Phase 2

bi-4SCAR CD19/79b T cells (bi-4SCAR CD19/79b T cells)

B Cell Malignancies · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleShenzhen Geno-Immune Medical In…Phase 2

bi-4SCAR GD2/CD70 T cells (bi-4SCAR GD2/CD70 T cells)

Cancer Disease · GD2

#GD2#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleShenzhen Geno-Immune Medical In…Phase 2

bi-4SCAR PSMA/CD70 T cells (bi-4SCAR PSMA/CD70 T cells)

Cancer Disease · PSMA

#PSMA#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
AntibodystaleAmgenPhase 1

blinatumomab and auto-HSCT "sandwich " strategy (blinatumomab and auto-HSCT "sandwich " strategy)

B-cell Acute Lymphoblastic Leukemia · B-cell Acute Lymphoblastic Leukemia

#B-cellAcuteLymphoblasticLeukemia#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleSingapore General HospitalPhase 1

bortezomib, rituximab, ifosphamide, etoposide, carboplatin (bortezomib, rituximab, ifosphamide, etoposide, carboplatin)

Diffuse Large B-Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
ADCBiologicstaleMabwell (Shanghai) Bioscience C…Phase 1

bulumtatug fuvedotin (bulumtatug fuvedotin)

Triple Negative Breast Cancer · Triple Negative Breast Cancer

#TripleNegativeBreastCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
CGTBiologicstaleUniversity of PennsylvaniaPhase 1

cMet RNA CAR T cells (cMet RNA CAR T cells)

Metastatic Breast Cancer; Triple Negative Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

cTACE+Atirizumab+Bevacizumab (cTACE+Atirizumab+Bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleCentre Francois BaclesseApproved

nivolumab (Opdivo, cabozantinib and nivolumab)

Renal Cell Carcinoma (Kidney Cancer); Metastatic Renal Cell Carcinoma · Renal Cell Carcinoma (Kidney Cancer)

#RenalCellCarcinomaKidneyCancer#Antibody#Approved#항체#면역항체+3
효능 ORR 25%임상시험 1상태 RECRUITING

167 / 177 페이지

← 이전다음 →